1. World Health Organization. Guidelines on cotrimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. 2006 Geneva,Switzerland. http://apps.who.int/iris/bitstream/handle/10665/43557/9789241594707_eng.pdf;jsessionid=B0B8C8A79E7FEDC435CB4F530B53CA90?sequence=1. Accessed 3 Jun 2023.
2. Grimwade K, Swingler G. Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV. Cochrane Database Syst Rev. 2003;2003(3):CD003108. https://doi.org/10.1002/14651858.CD003108.
3. Mekelle, University. College of Health Sciences. Ayder referral Hospital. https://ayder.info/index.php/about-us. Accessed 11 Feb 2020.
4. 2014 World Health Organization. Guidelines on Post Exposure Prophylaxis for HIV and the Use of Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Adults, Adolescents and Children: Recommendations for a Public Health Approach: December 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: WHO, Dec. https://www.ncbi.nlm.nih.gov/books/NBK298964/. Accessed 5 Jun 2023.
5. Mehta S, Moore RD, Graham NM. Potential factors affecting adherence with HIV therapy. AIDS. 1997;11(14):1665-70. https://doi.org/10.1097/00002030-199714000-00002. PMID: 9386800.